Tag: Lecanemab
EISAI PUBLISHES SOCIETAL VALUE OF LECANEMAB USING PHASE 3 CLARITY AD...
TOKYO, March 19, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced the publication of updated results from...
BioArctic: Lecanemab receives priority review status in Japan – Press...
STOCKHOLM, Jan. 30, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the application for manufacturing and...
Lecanemab Receives Priority Review Status in Japan – Press Release
TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen...
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad...
TOKYO, Nov 30, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the results from Eisai's large global...